Cargando…
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)
Along with hydration and urinary alkalinization, allopurinol has been the standard agent for the management of hyperuricemia in patients with a high tumor burden at risk of tumor lysis syndrome; however, this agent often fails to prevent and treat this complication effectively. Rasburicase (recombin...
Autores principales: | Pession, Andrea, Melchionda, Fraia, Castellini, Claudia |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727789/ https://www.ncbi.nlm.nih.gov/pubmed/19707436 |
Ejemplares similares
-
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
por: Cammalleri, Lisa, et al.
Publicado: (2007) -
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
por: Alakel, Nael, et al.
Publicado: (2017) -
The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase
por: Najjari, Abbas, et al.
Publicado: (2021) -
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy
por: Dinnel, Jennifer, et al.
Publicado: (2015) -
Catalysis and Structure of Zebrafish Urate Oxidase Provide Insights into the Origin of Hyperuricemia in Hominoids
por: Marchetti, Marialaura, et al.
Publicado: (2016)